Kane Biotech Inc.

KNE

CA4838092084

Biotechnology & Medical Research

Market Closed - Toronto S.E. Other stock markets 19:32:49 07/06/2024 BST			5-day change	1st Jan Change
0.13 ^CAD	0.00%		+4.00%	+62.50%

05-23	Kane Biotech Q1 Loss Widens Despite Revenue Gains; to Report a Q2 Gain Following Sale of STEM Animal Health	MT
05-23	Kane Biotech Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Kane Biotech Inc. Announces Changes to Its Board of Directors

March 01, 2023 at 01:56 pm

Kane Biotech Inc. announced that it has accepted the resignations of Mark Nawacki, Sarah Prichard and Allan Mandelzys as members of the board of directors of the Company effective immediately.

Latest news about Kane Biotech Inc.

Kane Biotech Q1 Loss Widens Despite Revenue Gains; to Report a Q2 Gain Following Sale of STEM Animal Health	05-23	MT
Kane Biotech Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-23	CI
Transcript : Kane Biotech Inc. - Shareholder/Analyst Call	05-22
Kane Biotech Expands Wound Care Portfolio with Patented Schultz Biofilm Wound Map	05-15	MT
Transcript : Kane Biotech Inc. - Special Call	04-18
Kane Biotech Up 12% After Reporting Closing of STEM Animal Health Sale	04-15	MT
Dechra Veterinary Products, Inc. completed the acquisition of 66.66% stake in STEM Animal Health Inc. from Kane Biotech Inc..	04-14	CI
Kane Biotech Agrees to Sell its Interest in STEM Animal Health for US$8 Million	04-11	MT
Transcript : Kane Biotech Inc., Q4 2023 Earnings Call, Mar 26, 2024	03-26
Kane Biotech Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-26	CI
Kane Biotech Brief: Says otal revenue for the three months ended December 31, 2023 was $764,997	03-26	MT
Kane Biotech Extends Exclusivity Period on its Offer for its Interest in STEM Animal Health	03-20	MT
Kane Biotech Inc. Appoints Dr. Robert Huizinga as Director and Executive Chair	02-22	CI
Transcript : Kane Biotech Inc. - Shareholder/Analyst Call	02-20
Kane Biotech Inc. Files New Patent on Revyvetm Antimicrobial Wound Gel Spray	01-31	CI
Kane Biotech Announces Correction to Press Release	12-29	MT
Kane Biotech Inc. Announces Amendment to Its Credit Facility	12-28	CI
Kane Biotech Gains 6% As Says To Sell Interest In STEM Animal Health	12-20	MT
Kane Biotech To Sell Interest In STEM Animal Health	12-20	MT
An undisclosed buyer signed a non-binding offer to acquire an unknown stake in STEM Animal Health Inc. from Kane Biotech Inc..	12-19	CI
An undisclosed buyer signed a non-binding offer to acquire an unknown entire stake in STEM Animal Health Inc. from Kane Biotech Inc..	12-19	CI
Transcript : Kane Biotech Inc., Q3 2023 Earnings Call, Nov 28, 2023	11-28
Kane Biotech Third-Quarter Loss Widens Despite Improved Revenue	11-28	MT
Kane Biotech Brief: Loss for Q3 of 2023 was ($1,197,889), an increase of 41% compared to ($851,597) for the quarter ended September 30, 2022	11-28	MT
Kane Biotech Brief: Total revenue for three months ended September 30, 2023 was $717,852, an increase of 26% compared to $571,686 in three months ended September 30, 2022	11-28	MT

Kane Biotech Inc. is a Canada-based biotechnology company. The Company is engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. It has a portfolio of biotechnologies and products, which includes StrixNB, DispersinB, Aledex, bluestem, bluestem, silkstem, goldstem, coactiv+, coactiv+, DermaKB and DermaKB Biofilm. Its Wound Care & Surgical division is focused on the product development of DispersinB for applications in chronic wound care. Its bluestem product line includes water additives, chews, spray and dental wipes. Its other products in development stage include Coactiv+, antimicrobial wound rinse for use in acute and chronic wounds; Coactiv+, antimicrobial surgical hydrogel for use in surgical and acute wounds, and DispersinB Gel for prosthetic joint infection. It also provides Scalp Detoxifier, Shampoo and Shampoo Bars. Its primary markets for its technologies are animal health and human health.

Sector

Biotechnology & Medical Research

Calendar

21/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
KANE BIOTECH INC.	+62.50%	12.52M
MODERNA, INC.	+51.85%	57.87B
LONZA GROUP AG	+41.42%	40.25B
IQVIA HOLDINGS INC.	-5.25%	39.94B
CELLTRION, INC.	-5.16%	28.54B
ICON PUBLIC LIMITED COMPANY	+12.79%	26.4B
ALNYLAM PHARMACEUTICALS, INC.	-20.18%	19.33B
MEDPACE HOLDINGS, INC.	+30.88%	12.4B
BIO-TECHNE CORPORATION	+0.61%	12.23B
UNITED THERAPEUTICS CORPORATION	+25.06%	12.2B

Other Biotechnology & Medical Research

Kane Biotech Inc.

Equities

KNE

CA4838092084

Biotechnology & Medical Research

Kane Biotech Inc. Announces Changes to Its Board of Directors

Latest news about Kane Biotech Inc.

Chart Kane Biotech Inc.

Company Profile

Income Statement Evolution

Sector Other Biotechnology & Medical Research